Concentric cardiac hypertrophy is a thickening of the myocardium which results in a decrease in size of the chamber of the heart, including the left and right ventricles. While hypertrophy can eventually normalize wall tension, it is associated with an unfavorable outcome and threatens affected patients with sudden death or progression to overt heart failure.
A common cause of cardiac hypertrophy is high blood pressure (hypertension) and heart valve stenosis.
Preclinical services offered
- Drug screening in in vivo (rat, mouse), in vitro and ex vivo models
- Evaluation of compounds effects on ventricular remodeling and dysfunction
- Combined disease models: Left ventricular overload with risk factors and co-morbidities such as hyperlipemia obesity and diabetes
Gold standard models to study pressure overload-induced cardiac hypertrophy and transition to heart failure.
View our factsheet by clicking on the document on the right.
In vivo models
- Thoracic aortic banding or Transverse aortic constriction (TAC model) (rat, mouse) is a well-established surgical procedure increasing the resistance to blood flow out of the heart leading to cardiac hypertrophy and mimicking human aortic stenosis.
Ex vivo / vitro assays
- Langendorff heart model
- Isolated cardiomyocytes
We propose a wide range of techniques to deliver key end-points: Echocardiography, Electrocardiogram, Millar probes, Telemetry, Immunohistochemistry, Myocyte Calcium and Contractility Recording System, Biochemistry and Molecular Biology.
All of our studies are designed following our clients’ requests, please contact us for more information.